

ASX Release

Extension of Closing Date of Entitlement Offer

Melbourne, Australia - (16 June, 2016) – Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) advises that due to the requirement for the Company to send out a Replacement Prospectus to shareholders, and in response to shareholder requests, the Company will be extending the closing date for the acceptance of applications for the 1 for 3 pro rata non-renounceable Entitlement Offer.

The closing date for the Entitlement Offer is now 5.00pm (Melbourne time), Tuesday 28 June 2016.

The Entitlement Offer is conducted at an issue price of 9.0 cents per share, with one free attaching option for every two new shares issued (exercisable at 18 cents; expiring 30 June 2018). Shareholders can apply for securities in excess of their entitlement via the Top-Up Facility.

The revised timetable for the remaining dates are set out below:

Item	Date*
Extraordinary meeting to approve Tranche 2 Placement and Placement Options	22 June 2016
Allotment of Shares issued under the Tranche 2 Placement	23 June 2016
Entitlement Offer closes (5.00pm, Sydney time)	28 June 2016
New Shares quoted on deferred settlement basis	29 June 2016
Announcement of results of Entitlement Offer and under-subscriptions	29 June 2016
Allotment of New Shares issued under the Entitlement Offer	30 June 2016
Allotment of Placement Options	30 June 2016
Despatch of holding statements for New Shares issued under the Entitlement Offer	30 June 2016
Normal ASX trading for New Shares issued under the Entitlement Offer commences	1 July 2016

**This timetable remains indicative and subject to change. PTX reserves the right, subject to the listing rules of the ASX (Listing Rules), the Corporations Act 2001 (Cth) (Corporations Act) and other applicable laws to vary any or all of the dates of the Entitlement Offer, including the Closing Date, without prior notice.*

ENDS



About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.

The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

